Additionally, it has been demonstrated that microRNAs directly targeting MKK4 are downregulated in prostate cancer tissues and cell lines, making MKK4 a promising target for prostate cancer therapy [72]. The gene discussed is MAP2K4; the disease is prostate carcinoma.